Dipeptidyl peptidase-4 and adenosine deaminase enzyme levels in polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in reproductive age women and insulin resistance (IR) and hyperinsulinism play a critical role in the pathogenesis. Glucagon-like peptide-1 (GLP-1), promotes insulin secretion, inhibits glucagon secretion. GLP-1 is degraded...

Full description

Saved in:
Bibliographic Details
Published in:Gynecological endocrinology 2019-02, Vol.35 (2), p.138-141
Main Authors: Öztürk, Bahadır, Gürbüz, Ali Sami, Durak, Zahide Esra, Öztürk, Hasan Serdar
Format: Article
Language:English
Subjects:
Adenosine deaminase
dipeptidyl peptidase-4
Polycystic ovary syndrome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c366t-dcb641dceffaa9e40163ec9dc17082df4001081507741c963c6338c3b4eb0b433
cites cdi_FETCH-LOGICAL-c366t-dcb641dceffaa9e40163ec9dc17082df4001081507741c963c6338c3b4eb0b433
container_end_page 141
container_issue 2
container_start_page 138
container_title Gynecological endocrinology
container_volume 35
creator Öztürk, Bahadır
Gürbüz, Ali Sami
Durak, Zahide Esra
Öztürk, Hasan Serdar
description Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in reproductive age women and insulin resistance (IR) and hyperinsulinism play a critical role in the pathogenesis. Glucagon-like peptide-1 (GLP-1), promotes insulin secretion, inhibits glucagon secretion. GLP-1 is degraded by dipeptidyl peptidase-4 (DPP-4). DPP-4, also interacts with adenosine deaminase (ADA). Therefore, IR may have a significant connection with ADA activity. The aim of this study is to compare levels of DPP-4 and ADA enzymes in PCOS and infertile patients. Forty-four patients with PCOS and 44 infertile patients with normal ovarian reserve were enrolled in the study. Serum ADA, DPP-4, AMH, glucose and insulin levels were measured. HOMA-IR method was used to assess insulin sensitivity. ADA, DPP-4, AMH, HOMA-IR (p 
doi_str_mv 10.1080/09513590.2018.1505847
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_09513590_2018_1505847</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2130058770</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-dcb641dceffaa9e40163ec9dc17082df4001081507741c963c6338c3b4eb0b433</originalsourceid><addsrcrecordid>eNp9kLtO7DAQQC0EguXxCffKJU2W8dqJkw7E5SUh0UBBZTn2RDJy7GBnQeHrb1a7UFLNSHPmdQj5w2DJoIYLaErGywaWK2D1kpVQ1kLukQUTkhcgq2qfLDZMsYGOyHHObwCMC7k6JEcceCOYaBbk9Z8bcBidnTzdJjpjIagOlmqLIWYXkFrUvQtzhWL4mnqkHj_QZ-oCHaKfzJRHZ2j80GmieQo2xR5PyUGnfcazXTwhL7c3z9f3xePT3cP11WNheFWNhTVtJZg12HVaNyiAVRxNYw2TUK9sJ-aroZ7_k1Iw01TcVJzXhrcCW2gF5yfkfDt3SPF9jXlUvcsGvdcB4zqrFeMwy5ESZrTcoibFnBN2akiun49WDNTGqvq2qjZW1c7q3Pd3t2Ld9mh_ur41zsDlFnChi6nXnzF5q0Y9-Zi6pINxWfHfd_wHQc6HRg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2130058770</pqid></control><display><type>article</type><title>Dipeptidyl peptidase-4 and adenosine deaminase enzyme levels in polycystic ovary syndrome</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Öztürk, Bahadır ; Gürbüz, Ali Sami ; Durak, Zahide Esra ; Öztürk, Hasan Serdar</creator><creatorcontrib>Öztürk, Bahadır ; Gürbüz, Ali Sami ; Durak, Zahide Esra ; Öztürk, Hasan Serdar</creatorcontrib><description>Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in reproductive age women and insulin resistance (IR) and hyperinsulinism play a critical role in the pathogenesis. Glucagon-like peptide-1 (GLP-1), promotes insulin secretion, inhibits glucagon secretion. GLP-1 is degraded by dipeptidyl peptidase-4 (DPP-4). DPP-4, also interacts with adenosine deaminase (ADA). Therefore, IR may have a significant connection with ADA activity. The aim of this study is to compare levels of DPP-4 and ADA enzymes in PCOS and infertile patients. Forty-four patients with PCOS and 44 infertile patients with normal ovarian reserve were enrolled in the study. Serum ADA, DPP-4, AMH, glucose and insulin levels were measured. HOMA-IR method was used to assess insulin sensitivity. ADA, DPP-4, AMH, HOMA-IR (p &lt; .05) and insulin levels (p &lt; .01) were found to be increased in PCOS patients. Considering all study participants AMH levels were found to be positively correlated with ADA (r: 0.734) and DPP-4 (r: 0.449) levels. Also ADA levels were found to be positively correlated with DPP-4 (r: 0.472), insulin (r: 0.216) and HOMA-IR (r: 0.223). Our findings about the elevation of DPP-4 levels in patients with PCOS suggest that the use of DPP-4 inhibitors may be beneficial in treatment of these patients.</description><identifier>ISSN: 0951-3590</identifier><identifier>EISSN: 1473-0766</identifier><identifier>DOI: 10.1080/09513590.2018.1505847</identifier><identifier>PMID: 30394149</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Adenosine deaminase ; dipeptidyl peptidase-4 ; Polycystic ovary syndrome</subject><ispartof>Gynecological endocrinology, 2019-02, Vol.35 (2), p.138-141</ispartof><rights>2018 Informa UK Limited, trading as Taylor &amp; Francis Group 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-dcb641dceffaa9e40163ec9dc17082df4001081507741c963c6338c3b4eb0b433</citedby><cites>FETCH-LOGICAL-c366t-dcb641dceffaa9e40163ec9dc17082df4001081507741c963c6338c3b4eb0b433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30394149$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Öztürk, Bahadır</creatorcontrib><creatorcontrib>Gürbüz, Ali Sami</creatorcontrib><creatorcontrib>Durak, Zahide Esra</creatorcontrib><creatorcontrib>Öztürk, Hasan Serdar</creatorcontrib><title>Dipeptidyl peptidase-4 and adenosine deaminase enzyme levels in polycystic ovary syndrome</title><title>Gynecological endocrinology</title><addtitle>Gynecol Endocrinol</addtitle><description>Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in reproductive age women and insulin resistance (IR) and hyperinsulinism play a critical role in the pathogenesis. Glucagon-like peptide-1 (GLP-1), promotes insulin secretion, inhibits glucagon secretion. GLP-1 is degraded by dipeptidyl peptidase-4 (DPP-4). DPP-4, also interacts with adenosine deaminase (ADA). Therefore, IR may have a significant connection with ADA activity. The aim of this study is to compare levels of DPP-4 and ADA enzymes in PCOS and infertile patients. Forty-four patients with PCOS and 44 infertile patients with normal ovarian reserve were enrolled in the study. Serum ADA, DPP-4, AMH, glucose and insulin levels were measured. HOMA-IR method was used to assess insulin sensitivity. ADA, DPP-4, AMH, HOMA-IR (p &lt; .05) and insulin levels (p &lt; .01) were found to be increased in PCOS patients. Considering all study participants AMH levels were found to be positively correlated with ADA (r: 0.734) and DPP-4 (r: 0.449) levels. Also ADA levels were found to be positively correlated with DPP-4 (r: 0.472), insulin (r: 0.216) and HOMA-IR (r: 0.223). Our findings about the elevation of DPP-4 levels in patients with PCOS suggest that the use of DPP-4 inhibitors may be beneficial in treatment of these patients.</description><subject>Adenosine deaminase</subject><subject>dipeptidyl peptidase-4</subject><subject>Polycystic ovary syndrome</subject><issn>0951-3590</issn><issn>1473-0766</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kLtO7DAQQC0EguXxCffKJU2W8dqJkw7E5SUh0UBBZTn2RDJy7GBnQeHrb1a7UFLNSHPmdQj5w2DJoIYLaErGywaWK2D1kpVQ1kLukQUTkhcgq2qfLDZMsYGOyHHObwCMC7k6JEcceCOYaBbk9Z8bcBidnTzdJjpjIagOlmqLIWYXkFrUvQtzhWL4mnqkHj_QZ-oCHaKfzJRHZ2j80GmieQo2xR5PyUGnfcazXTwhL7c3z9f3xePT3cP11WNheFWNhTVtJZg12HVaNyiAVRxNYw2TUK9sJ-aroZ7_k1Iw01TcVJzXhrcCW2gF5yfkfDt3SPF9jXlUvcsGvdcB4zqrFeMwy5ESZrTcoibFnBN2akiun49WDNTGqvq2qjZW1c7q3Pd3t2Ld9mh_ur41zsDlFnChi6nXnzF5q0Y9-Zi6pINxWfHfd_wHQc6HRg</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Öztürk, Bahadır</creator><creator>Gürbüz, Ali Sami</creator><creator>Durak, Zahide Esra</creator><creator>Öztürk, Hasan Serdar</creator><general>Taylor &amp; Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190201</creationdate><title>Dipeptidyl peptidase-4 and adenosine deaminase enzyme levels in polycystic ovary syndrome</title><author>Öztürk, Bahadır ; Gürbüz, Ali Sami ; Durak, Zahide Esra ; Öztürk, Hasan Serdar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-dcb641dceffaa9e40163ec9dc17082df4001081507741c963c6338c3b4eb0b433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adenosine deaminase</topic><topic>dipeptidyl peptidase-4</topic><topic>Polycystic ovary syndrome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Öztürk, Bahadır</creatorcontrib><creatorcontrib>Gürbüz, Ali Sami</creatorcontrib><creatorcontrib>Durak, Zahide Esra</creatorcontrib><creatorcontrib>Öztürk, Hasan Serdar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecological endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Öztürk, Bahadır</au><au>Gürbüz, Ali Sami</au><au>Durak, Zahide Esra</au><au>Öztürk, Hasan Serdar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dipeptidyl peptidase-4 and adenosine deaminase enzyme levels in polycystic ovary syndrome</atitle><jtitle>Gynecological endocrinology</jtitle><addtitle>Gynecol Endocrinol</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>35</volume><issue>2</issue><spage>138</spage><epage>141</epage><pages>138-141</pages><issn>0951-3590</issn><eissn>1473-0766</eissn><abstract>Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in reproductive age women and insulin resistance (IR) and hyperinsulinism play a critical role in the pathogenesis. Glucagon-like peptide-1 (GLP-1), promotes insulin secretion, inhibits glucagon secretion. GLP-1 is degraded by dipeptidyl peptidase-4 (DPP-4). DPP-4, also interacts with adenosine deaminase (ADA). Therefore, IR may have a significant connection with ADA activity. The aim of this study is to compare levels of DPP-4 and ADA enzymes in PCOS and infertile patients. Forty-four patients with PCOS and 44 infertile patients with normal ovarian reserve were enrolled in the study. Serum ADA, DPP-4, AMH, glucose and insulin levels were measured. HOMA-IR method was used to assess insulin sensitivity. ADA, DPP-4, AMH, HOMA-IR (p &lt; .05) and insulin levels (p &lt; .01) were found to be increased in PCOS patients. Considering all study participants AMH levels were found to be positively correlated with ADA (r: 0.734) and DPP-4 (r: 0.449) levels. Also ADA levels were found to be positively correlated with DPP-4 (r: 0.472), insulin (r: 0.216) and HOMA-IR (r: 0.223). Our findings about the elevation of DPP-4 levels in patients with PCOS suggest that the use of DPP-4 inhibitors may be beneficial in treatment of these patients.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>30394149</pmid><doi>10.1080/09513590.2018.1505847</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0951-3590
ispartof Gynecological endocrinology, 2019-02, Vol.35 (2), p.138-141
issn 0951-3590
1473-0766
language eng
recordid cdi_crossref_primary_10_1080_09513590_2018_1505847
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Adenosine deaminase
dipeptidyl peptidase-4
Polycystic ovary syndrome
title Dipeptidyl peptidase-4 and adenosine deaminase enzyme levels in polycystic ovary syndrome
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T06%3A25%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dipeptidyl%20peptidase-4%20and%20adenosine%20deaminase%20enzyme%20levels%20in%20polycystic%20ovary%20syndrome&rft.jtitle=Gynecological%20endocrinology&rft.au=%C3%96zt%C3%BCrk,%20Bahad%C4%B1r&rft.date=2019-02-01&rft.volume=35&rft.issue=2&rft.spage=138&rft.epage=141&rft.pages=138-141&rft.issn=0951-3590&rft.eissn=1473-0766&rft_id=info:doi/10.1080/09513590.2018.1505847&rft_dat=%3Cproquest_cross%3E2130058770%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c366t-dcb641dceffaa9e40163ec9dc17082df4001081507741c963c6338c3b4eb0b433%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2130058770&rft_id=info:pmid/30394149&rfr_iscdi=true